BioPharmSignal logoBioPharmSignal

Biotech News

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Adlai Nortye Ltd. (ANL)Adlai Nortye Ltd.2026-06-25 13:46 ESTClinical readout

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has

Open original release

Related news

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Reports Full Year 2024 Financial Results and Business Updates

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Announces Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye to Participate in Upcoming Investor Conferences

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

View all latest news

Adlai Nortye Ltd.

阿诺医药 is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ANLAdlai Nortye Ltd.2026-06-26 06:21 EST

Adlai Nortye Reports Full Year 2024 Financial Results and Business Updates

ANLAdlai Nortye Ltd.2026-06-26 06:21 EST

Adlai Nortye Announces Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC

ANLAdlai Nortye Ltd.2026-06-26 06:21 EST

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ANLAdlai Nortye Ltd.2026-06-26 06:21 EST

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ANLAdlai Nortye Ltd.2026-06-26 06:21 EST

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States